> The FDA has put Cell Therapeutics' Xyotax cancer drug on the regulatory fast track. The news helped boost the company's stock in premarket trading. Report
> A late-stage study of Celgene's cancer drug Revlimid was temporarily suspended, evidently to allow patients to switch to a different treatment regiment with better survival prospects. Report
> Neurochem says the FDA has extended the review period for the kidney drug Kiacta so it can review additional information. Report
> FDA staffers say there might be a link between Roche weight-loss drug Xenical and gallstones. The memo was spurred by an upcoming panel discussion on expanding the use of Xenical to children. Report
> Illumina says it will close a facility in Wallingford, CT and move the operations to San Diego. Release
> The CDC is looking to open a lab in Hawaii to move it closer to Asia. Report
> An experimental cancer therapy may help point the way to a new treatment for clinical depression. Report
> Scientists at McGill University are researching the effects of a gene linked to memory enhancement in hopes of developing a new therapy that could be used to improve memory in healthy people as well as treat dementia. Report
And Finally... A drug researcher is turning to patients to financially support his work. Report